TRAUMA
No difference with gabapentin versus placebo following rib fracture in critically ill patients
Injury. 2018 Sep;49(9):1693-1698. doi: 10.1016/j.injury.2018.06.00240 patients with one or more rib fractures were randomized to the addition of either gabapentin 300mg or placebo three times daily to a mutlimodal analgesia protocol. Patients were primarily assessed for analgesic outcomes over the first 7 days of treatment, including pain scores and narcotic consumption. Results on these measures demonstrated no significant differences between groups on any day. In addition, data on incentive spirometry during hospitalization, and general and disease-specific quality of life at 1 month follow-up, demonstrated no significant differences between groups. No cases of pneumonia or respiratory failure were noted in either group.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
